Clinical trials investigating the use of celecoxib, a selective COX-2 inhibitor, as an adjuvant therapy to sensitize chemotherapy effects on patients with breast, lung, colon cancer, and radiotherapy on non-metastatic prostate cancers have demonstrated no evidence of treatment benefit on cancer outcomes as well as no increase in toxic events related to the medication use in breast, lung and prostate cancer patients, while increased hypertension and creatinine elevation risks in colon cancer patients (54, 55, 80, 81). This evidence concerns the gene PTGS2 and Familial prostate cancer.